Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Drug-induced Bile Duct Injury - A Short Review

Author(s): Inna Dobreva* and Petko Karagyozov

Volume 21, Issue 4, 2020

Page: [256 - 259] Pages: 4

DOI: 10.2174/1389200221666200420100129

Price: $65

Abstract

The liver represents the major site of drug metabolism, i.e. the key organ in the processes of detoxification and elimination of drugs from the organism. It is therefore often affected by toxic metabolites and suffers sometimes fatal consequences. The spectrum of pathologies differs by the cell type primarily damaged and the group of the cholangiopathies includes those conditions affecting the bile duct epithelium or the cholangiocytes. They can range from transient cholestasis to vanishing bile duct syndrome and sclerosing cholangitis, both leading eventually to the development of biliary fibrosis and cirrhosis.

In this review article, we focus on the etiology, predisposing factors, clinical manifestations, and histopathological characteristics of bile duct injury as a consequence of drug treatment and discuss separately the different bile duct pathologies.

Keywords: Drug-induced bile duct injury, histopathology, bile duct, cholangiocyte, cholestasis, vanishing bile duct syndrome (VBDS).

« Previous Next »
[1]
Strazzabosco, M.; Fabris, L.; Spirli, C. Pathophysiology of cholangiopathies. J. Clin. Gastroenterol., 2005, 39(4)(Suppl. 2), S90-S102.
[http://dx.doi.org/10.1097/01.mcg.0000155549.29643.ad] [PMID: 15758666]
[2]
Visentin, M.; Lenggenhager, D.; Gai, Z.; Kullak-Ublick, G.A. Drug-induced bile duct injury. Biochim. Biophys. Acta Mol. Basis Dis., 2018, 1864(4 Pt B), 1498-1506.
[http://dx.doi.org/10.1016/j.bbadis.2017.08.033] [PMID: 28882625]
[3]
Österreicher, C.H.; Trauner, M. Xenobiotic-induced liver injury and fibrosis. Expert Opin. Drug Metab. Toxicol., 2012, 8(5), 571-580.
[http://dx.doi.org/10.1517/17425255.2012.674511] [PMID: 22452290]
[4]
Kolarić, T.O.; Ninčević, V.; Smolić, R.; Smolić, M.; Wu, G.Y. Mechanisms of hepatic cholestatic drug injury. J. Clin. Transl. Hepatol., 2019, 7(1), 86-92.
[PMID: 30944824]
[5]
Sundaram, V.; Bjornsson, E. Drug-induced cholestasis. Hepatol Commun, 2017, 1, 726-735.
[6]
Hussaini, S.H.; Farrington, E.A. Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf., 2007, 6(6), 673-684.
[http://dx.doi.org/10.1517/14740338.6.6.673] [PMID: 17967156]
[7]
Yang, K.; Köck, K.; Sedykh, A.; Tropsha, A.; Brouwer, K.L. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci., 2013, 102(9), 3037-3057.
[http://dx.doi.org/10.1002/jps.23584] [PMID: 23653385]
[8]
Hofmann, A.F. Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol., 1995, 27(2), 106-113.
[PMID: 7579591]
[9]
Trauner, M.; Fickert, P.; Wagner, M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis., 2007, 27(1), 77-98.
[http://dx.doi.org/10.1055/s-2006-960172] [PMID: 17295178]
[10]
Pauli-Magnus, C.; Meier, P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology, 2006, 44(4), 778-787.
[http://dx.doi.org/10.1002/hep.21359] [PMID: 17006912]
[11]
Lang, C.; Meier, Y.; Stieger, B.; Beuers, U.; Lang, T.; Kerb, R.; Kullak-Ublick, G.A.; Meier, P.J.; Pauli-Magnus, C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics, 2007, 17(1), 47-60.
[http://dx.doi.org/10.1097/01.fpc.0000230418.28091.76] [PMID: 17264802]
[12]
Trauner, M.; Meier, P.J.; Boyer, J.L. Molecular pathogenesis of cholestasis. N. Engl. J. Med., 1998, 339(17), 1217-1227.
[http://dx.doi.org/10.1056/NEJM199810223391707] [PMID: 9780343]
[13]
García Rodríguez, L.A.; Stricker, B.H.; Zimmerman, H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch. Intern. Med., 1996, 156(12), 1327-1332.
[http://dx.doi.org/10.1001/archinte.156.12.1327] [PMID: 8651842]
[14]
Desmet, V.J. Vanishing bile duct syndrome in drug-induced liver disease. J. Hepatol., 1997, 26(Suppl. 1), 31-35.
[http://dx.doi.org/10.1016/S0168-8278(97)82330-6] [PMID: 9138126]
[15]
Tabibian, J.H.; Masyuk, A.I.; Masyuk, T.V.; O’Hara, S.P.; LaRusso, N.F. Physiology of cholangiocytes. Compr. Physiol., 2013, 3(1), 541-565.
[PMID: 23720296]
[16]
Geubel, A.P.; Sempoux, C.L. Drug and toxin-induced bile duct disorders. J. Gastroenterol. Hepatol., 2000, 15(11), 1232-1238.
[PMID: 11129214]
[17]
Björnsson, E. Review article: drug-induced liver injury in clinical practice. Aliment. Pharmacol. Ther., 2010, 32(1), 3-13.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04320.x] [PMID: 20374223]
[18]
Chalasani, N.; Björnsson, E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology, 2010, 138(7), 2246-2259.
[http://dx.doi.org/10.1053/j.gastro.2010.04.001] [PMID: 20394749]
[19]
Olsson, R.; Wiholm, B-E.; Sand, C.; Zettergren, L.; Hultcrantz, R.; Myrhed, M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J. Hepatol., 1992, 15(1-2), 154-161.
[http://dx.doi.org/10.1016/0168-8278(92)90029-O] [PMID: 1506634]
[20]
de Abajo, F.J.; Montero, D.; Madurga, M.; García Rodríguez, L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol., 2004, 58(1), 71-80.
[http://dx.doi.org/10.1111/j.1365-2125.2004.02133.x] [PMID: 15206996]
[21]
Lammert, C.; Einarsson, S.; Saha, C.; Niklasson, A.; Bjornsson, E.; Chalasani, N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology, 2008, 47(6), 2003-2009.
[http://dx.doi.org/10.1002/hep.22272] [PMID: 18454504]
[22]
Daly, A.K.; Donaldson, P.T.; Bhatnagar, P.; Shen, Y.; Pe’er, I.; Floratos, A.; Daly, M.J.; Goldstein, D.B.; John, S.; Nelson, M.R.; Graham, J.; Park, B.K.; Dillon, J.F.; Bernal, W.; Cordell, H.J.; Pirmohamed, M.; Aithal, G.P.; Day, C.P. DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet., 2009, 41(7), 816-819.
[http://dx.doi.org/10.1038/ng.379] [PMID: 19483685]
[23]
Andrade, R.J.; Lucena, M.I.; Alonso, A.; García-Cortes, M.; García-Ruiz, E.; Benitez, R.; Fernández, M.C.; Pelaez, G.; Romero, M.; Corpas, R.; Durán, J.A.; Jiménez, M.; Rodrigo, L.; Nogueras, F.; Martín-Vivaldi, R.; Navarro, J.M.; Salmerón, J.; de la Cuesta, F.S.; Hidalgo, R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39(6), 1603-1612.
[http://dx.doi.org/10.1002/hep.20215] [PMID: 15185301]
[24]
Bonkovsky, H.L.; Kleiner, D.E.; Gu, J.; Odin, J.A.; Russo, M.W.; Navarro, V.M.; Fontana, R.J.; Ghabril, M.S.; Barnhart, H.; Hoofnagle, J.H. U.S.D.I.L.I.N Investigators, . Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology, 2016, 65(4), 1267-1277.
[25]
Alpini, G.; Lenzi, R.; Sarkozi, L.; Tavoloni, N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J. Clin. Invest., 1988, 81(2), 569-578.
[http://dx.doi.org/10.1172/JCI113355] [PMID: 2448343]
[26]
Larrey, D.; Erlinger, S. Drug-induced cholestasis. Baillieres Clin. Gastroenterol., 1988, 2(2), 423-452.
[http://dx.doi.org/10.1016/0950-3528(88)90010-3] [PMID: 3044469]
[27]
Leon, M.P.; Bassendine, M.F.; Wilson, J.L.; Ali, S.; Thick, M.; Kirby, J.A. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology, 1996, 24(3), 561-567.
[http://dx.doi.org/10.1002/hep.510240317] [PMID: 8781325]
[28]
Perez, M.J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol., 2009, 15(14), 1677-1689.
[http://dx.doi.org/10.3748/wjg.15.1677] [PMID: 19360911]
[29]
Bhamidimarri, K.R.; Schiff, E. Drug-induced cholestasis.. Clin. Liver Dis., 2013, 17(4), 519-531, vii.,
[http://dx.doi.org/10.1016/j.cld.2013.07.015] [PMID: 24099015]
[30]
Herrero-Herrero, J-I.; García-Aparicio, J. Corticosteroid therapy in a case of severe cholestasic hepatitis associated with amoxicillin-clavulanate. J. Med. Toxicol., 2010, 6(4), 420-423.
[http://dx.doi.org/10.1007/s13181-010-0019-4] [PMID: 20237968]
[31]
Ko, Y.J.; Karanicolas, P.J. Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era. Curr. Oncol., 2014, 21(1), e116-e121.
[http://dx.doi.org/10.3747/co.21.1592] [PMID: 24523608]
[32]
Ito, K.; Ito, H.; Kemeny, N.E.; Gonen, M.; Allen, P.J.; Paty, P.B.; Fong, Y.; Dematteo, R.P.; Blumgart, L.H.; Jarnagin, W.R.; D’Angelica, M.I. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann. Surg. Oncol., 2012, 19(5), 1609-1617.
[http://dx.doi.org/10.1245/s10434-011-2102-8] [PMID: 21989666]
[33]
Sahin, M.; Eryilmaz, R.; Bulbuloglu, E. The effect of scolicidal agents on liver and biliary tree (experimental study). J. Invest. Surg., 2004, 17(6), 323-326.
[http://dx.doi.org/10.1080/08941930490524363] [PMID: 15764499]
[34]
Gudnason, H.O.; Björnsson, H.K.; Gardarsdottir, M.; Thorisson, H.M.; Olafsson, S.; Bergmann, O.M.; Björnsson, E.S. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig. Liver Dis., 2015, 47(6), 502-507.
[http://dx.doi.org/10.1016/j.dld.2015.03.002] [PMID: 25840876]

Rights & Permissions Print Cite
Article Metrics
31
3
© 2024 Bentham Science Publishers | Privacy Policy